BioSpace3h
As US Sales of Leqembi Lag, Eisai Eyes SubQ Approvals
The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
PMLiVE5h
International Alzheimer’s disease prevention trial in at-risk young adults begins
An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...
American Association of Individual Investors22h
Which Is a Better Investment, Biogen Inc. or Neurocrine Biosciences, Inc. Stock?
Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Meet the 24-year-old helping Lilly test a preventive Alzheimer’s drug
Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...
alzheimersnewstoday3h
Leqembi IV monthly maintenance dosing approved by FDA
The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.